Breast Biopsy Market by Product Type (Biopsy Needles, Guidance Systems, Biopsy Guns), Procedure Type (Core Needle Biopsy, Vacuum-Assisted Biopsy, Fine Needle Aspiration Biopsy), Guidance Modality, Biopsy Site, End User, Clinical Indication - Global Foreca
Description
The Breast Biopsy Market was valued at USD 1.90 billion in 2024 and is projected to grow to USD 2.02 billion in 2025, with a CAGR of 6.63%, reaching USD 3.17 billion by 2032.
A concise contextual introduction that frames clinical imperatives, procurement dynamics, and diagnostic priorities shaping breast biopsy decisions today
The breast biopsy landscape is undergoing a rapid convergence of clinical precision, patient experience, and operational efficiency. Advances in imaging and device ergonomics are reshaping how tissue sampling is planned and executed, while increasing outpatient care capacity and value-based payment considerations are changing provider procurement behavior. Stakeholders across radiology, oncology, and pathology are prioritizing diagnostic confidence, time-to-diagnosis, and workflow integration as central performance metrics.
This executive summary synthesizes the critical drivers, technology inflection points, clinical practice adaptations, and stakeholder priorities shaping current decision-making. It highlights how modality selection, procedural setting, and device features intersect with payer dynamics and supply chain realities to influence adoption pathways. Clinicians seek tools that reduce sampling variability and enable faster downstream treatment planning, while administrators demand solutions that optimize throughput without compromising quality. The result is a market environment that rewards demonstrable clinical outcomes, seamless integration with imaging systems, and commercially viable service models.
How imaging advances, device automation, and outpatient care models are redefining procedural choices and clinical workflows in breast biopsy delivery
Transformative shifts in breast biopsy practice are driven by parallel advances in imaging fidelity, device automation, and patient-centered care models. High-resolution ultrasound and multimodal image fusion now support more confident lesion targeting, reducing reliance on more invasive or disruptive approaches. At the same time, improvements in device ergonomics and automation have narrowed the skill gap between clinicians, enabling broader adoption in outpatient settings and expanding access to minimally invasive tissue sampling.
The rise of vacuum-assisted systems tailored for targeted excision and larger core volume retrieval is changing procedural algorithms, while enhanced fine needle aspiration technology is improving cytological yield in select indications. These technological shifts are reinforced by evolving care pathways that prioritize shorter procedures, lower complication rates, and faster diagnostic throughput. As a consequence, supply chain partners, manufacturers, and clinical leaders are aligning around interoperability, disposables management, and bundled procurement strategies that support predictable costs and consistent clinical outcomes.
Cumulative implications of 2025 tariff shifts on supply chains, procurement behaviors, and device cost strategies within the breast biopsy value chain
U.S. tariff adjustments in 2025 have had a layering effect on the broader breast biopsy ecosystem by influencing component sourcing, pricing strategies, and supplier diversification. Tariffs that target medical device components increase input costs for manufacturers who rely on international supply chains for alloys, polymers, and precision machining. In response, original equipment manufacturers have accelerated nearshoring and supplier qualification programs to mitigate tariff exposure while preserving device performance and regulatory compliance.
Procurement teams within health systems and ambulatory providers are reacting by emphasizing total cost of ownership over unit price, weighing longer-term service agreements and consumable cost trajectories more heavily than single-purchase metrics. For some vendors, tariff-induced cost pressure has incentivized product redesign to reduce reliance on affected components, while others have absorbed short-term margin impacts to maintain market access. Across the value chain, the net effect has been heightened attention to contractual flexibility, inventory resilience, and multi-sourcing strategies to ensure uninterrupted procedural capability and stable pricing for clinicians and patients.
Insightful segmentation analysis linking device technologies, procedural approaches, and care settings to clinical use cases and procurement priorities
Technology segmentation reveals differentiated clinical and operational use cases that influence procurement and deployment. Core needle biopsy devices, available in both automated and semi-automated variants, remain the workhorse for percutaneous tissue sampling where larger cores and reproducible sampling trajectories are prioritized; automated units appeal to high-volume settings seeking speed and consistency, while semi-automated systems trade some throughput for lower capital and training burdens. Fine needle aspiration needles, designed as echo enhanced or standard configurations, continue to support cytology-focused workflows and offer advantages in select lesion types where minimal invasiveness and rapid onsite evaluation are critical. Vacuum-assisted systems, offered as handheld or table configured platforms, expand the procedural spectrum by enabling larger-volume sampling and targeted excision that can reduce the need for subsequent diagnostic surgeries.
Procedure type segmentation highlights modality-specific clinical pathways that drive device choice and skill requirements. MRI-guided approaches, whether closed or open bore, are essential for lesions only visible on advanced imaging and demand coordination with radiology scheduling and MRI-safe instrumentation. Palpation-guided techniques persist in low-resource or immediate-access contexts with freehand or grid guided options that balance accessibility and precision. Stereotactic techniques, conducted prone or upright, remain central for calcification sampling and microcalcification-targeted workflows. Ultrasound-guided procedures, utilizing either 2D or 3D guidance, provide the most flexible and widely deployed approach, enabling real-time visualization, needle tracking, and point-of-care diagnostics.
End user segmentation underscores differing procurement priorities across settings. Ambulatory surgery centers, which include diagnostic and outpatient surgery centers, prioritize turnover efficiency, disposable management, and predictable procedure times. Hospitals, both private and public, require devices that integrate into multi-disciplinary pathways, align with institutional quality metrics, and support complex case mixes. Specialty clinics, encompassing oncology and radiology clinics, emphasize diagnostic accuracy, access to advanced modalities, and close collaboration with pathology services to shorten diagnostic intervals and streamline care pathways.
Regional dynamics and distinct adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape procurement, regulation, and clinical workflows
Regional dynamics influence clinical adoption, supply chain design, and regulatory strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical pathways increasingly favor outpatient and ambulatory models with strong payer focus on efficiency and patient experience; manufacturers and distributors must therefore emphasize reliability, consumable cost management, and clinician training to win in this environment. Europe, Middle East & Africa presents a heterogeneous landscape where national reimbursement frameworks, centralized procurement in some markets, and variable access to high-end imaging equipment shape adoption patterns; local regulatory nuances and distribution partnerships are critical for sustained market penetration.
Asia-Pacific demonstrates rapid modernization of imaging infrastructure in urban centers, coupled with a growing emphasis on minimally invasive procedures and domestic manufacturing capabilities. In many markets within the region, cost sensitivity is paired with willingness to adopt technologies that demonstrably reduce downstream surgical burden. Across all regions, regional supply chain resilience, regulatory compliance, and clinician education programs are common success factors for vendors seeking durable presence and clinical trust.
Evolving competitive strategies where product performance, integrated services, and interoperability determine long-term vendor advantage in breast biopsy markets
Competitive behavior in the breast biopsy domain is evolving from product-centric differentiation to ecosystem-centric value propositions. Leading manufacturers are increasingly bundling service agreements, training programs, and integrated disposables management into commercial offers to address hospital and outpatient buyer demands for predictable operating costs and reduced administrative overhead. Strategic partnerships between device makers and imaging system providers are advancing interoperability, enabling tighter integration of lesion targeting data and needle guidance for improved diagnostic yield.
Innovation focus has shifted toward features that reduce procedural variability, such as improved needle visualization, ergonomics that lower clinician fatigue, and device designs that simplify sterilization and inventory handling. Smaller and specialized vendors are finding opportunities by targeting niche clinical indications or by delivering point-of-care solutions that address gaps in access. Meanwhile, procurement sophistication among end users is increasing, with clinical and supply chain leaders jointly evaluating vendor value based on clinical evidence, training support, and lifecycle cost management rather than capital price alone.
Practical recommendations for manufacturers, providers, and purchasers to align innovation, evidence, and supply resilience with evolving clinical and commercial needs
Industry leaders should prioritize a set of pragmatic actions that align commercial, clinical, and operational objectives. First, invest in evidence-generation programs that demonstrate how device features translate to measurable clinical outcomes and operational efficiencies; robust real-world evidence and peer-reviewed clinical collaborations will accelerate clinician adoption. Second, redesign commercial models to emphasize total cost of ownership, offering flexible consumable bundles and service-level agreements that match the financial cadence of ambulatory centers and hospitals alike. Third, strengthen supply chain resilience through multi-sourcing, regional supplier qualification, and inventory optimization to reduce exposure to trade disruptions and tariff volatility.
Manufacturers should also pursue tighter interoperability with imaging platforms and pathology workflows to shorten diagnostic cycles and support integrated care pathways. Training and credentialing programs tailored to different procedure types and care settings will lower adoption barriers and reduce procedural variability. Finally, consider modular product architectures that allow incremental feature rollouts and enable customization for distinct clinical segments, thereby lowering entry barriers for resource-constrained environments while preserving pathways to upgrade as demand for advanced capabilities grows.
Transparent mixed-methods research design combining clinician interviews, procedural observation, and secondary clinical and regulatory sources to validate insights
This research synthesized primary and secondary methods to ensure a balanced understanding of clinical practice, procurement behavior, and technology trends. Primary inputs included structured interviews with radiologists, oncologists, pathology lab directors, ambulatory surgery center administrators, and supply chain leaders to capture operational realities and adoption barriers. These interviews were complemented by observational reviews of procedural workflows and device use in representative clinical settings to contextualize qualitative insights.
Secondary research encompassed peer-reviewed clinical literature, device regulatory filings, clinical guidelines, and publicly available hospital procurement documentation to triangulate trends and validate practice patterns. Findings were subjected to cross-validation through expert advisory panels and scenario testing to assess the robustness of insights across different procedural mixes and regional contexts. Data integrity checks and bias mitigation steps were applied throughout, including respondent sourcing diversity, anonymized synthesis of interview content, and transparent documentation of methodological limitations to support confident decision-making by readers.
A decisive synthesis showing how clinical innovation, operational efficiency, and supply resilience together determine future success in the breast biopsy arena
The breast biopsy landscape is at an inflection where technology, clinical workflow optimization, and commercial strategy intersect to influence future adoption and value creation. Advances in imaging and device design are expanding the range of minimally invasive diagnostic options while shifting procedural volume toward outpatient settings that demand efficiency and predictable costs. Concurrently, supply chain and tariff dynamics have elevated the importance of procurement resilience and total cost evaluation, prompting manufacturers to rethink design, sourcing, and commercial models.
For clinical leaders, the emphasis should remain on diagnostic accuracy, patient experience, and integration of pathology workflows to accelerate time-to-treatment. For commercial leaders, aligning evidence generation with buyer procurement criteria and offering flexible service models will be pivotal. Taken together, these forces create an opportunity for stakeholders who can deliver demonstrable clinical benefit, operational predictability, and adaptable commercial terms to secure sustained adoption and strategic advantage.
Note: PDF & Excel + Online Access - 1 Year
A concise contextual introduction that frames clinical imperatives, procurement dynamics, and diagnostic priorities shaping breast biopsy decisions today
The breast biopsy landscape is undergoing a rapid convergence of clinical precision, patient experience, and operational efficiency. Advances in imaging and device ergonomics are reshaping how tissue sampling is planned and executed, while increasing outpatient care capacity and value-based payment considerations are changing provider procurement behavior. Stakeholders across radiology, oncology, and pathology are prioritizing diagnostic confidence, time-to-diagnosis, and workflow integration as central performance metrics.
This executive summary synthesizes the critical drivers, technology inflection points, clinical practice adaptations, and stakeholder priorities shaping current decision-making. It highlights how modality selection, procedural setting, and device features intersect with payer dynamics and supply chain realities to influence adoption pathways. Clinicians seek tools that reduce sampling variability and enable faster downstream treatment planning, while administrators demand solutions that optimize throughput without compromising quality. The result is a market environment that rewards demonstrable clinical outcomes, seamless integration with imaging systems, and commercially viable service models.
How imaging advances, device automation, and outpatient care models are redefining procedural choices and clinical workflows in breast biopsy delivery
Transformative shifts in breast biopsy practice are driven by parallel advances in imaging fidelity, device automation, and patient-centered care models. High-resolution ultrasound and multimodal image fusion now support more confident lesion targeting, reducing reliance on more invasive or disruptive approaches. At the same time, improvements in device ergonomics and automation have narrowed the skill gap between clinicians, enabling broader adoption in outpatient settings and expanding access to minimally invasive tissue sampling.
The rise of vacuum-assisted systems tailored for targeted excision and larger core volume retrieval is changing procedural algorithms, while enhanced fine needle aspiration technology is improving cytological yield in select indications. These technological shifts are reinforced by evolving care pathways that prioritize shorter procedures, lower complication rates, and faster diagnostic throughput. As a consequence, supply chain partners, manufacturers, and clinical leaders are aligning around interoperability, disposables management, and bundled procurement strategies that support predictable costs and consistent clinical outcomes.
Cumulative implications of 2025 tariff shifts on supply chains, procurement behaviors, and device cost strategies within the breast biopsy value chain
U.S. tariff adjustments in 2025 have had a layering effect on the broader breast biopsy ecosystem by influencing component sourcing, pricing strategies, and supplier diversification. Tariffs that target medical device components increase input costs for manufacturers who rely on international supply chains for alloys, polymers, and precision machining. In response, original equipment manufacturers have accelerated nearshoring and supplier qualification programs to mitigate tariff exposure while preserving device performance and regulatory compliance.
Procurement teams within health systems and ambulatory providers are reacting by emphasizing total cost of ownership over unit price, weighing longer-term service agreements and consumable cost trajectories more heavily than single-purchase metrics. For some vendors, tariff-induced cost pressure has incentivized product redesign to reduce reliance on affected components, while others have absorbed short-term margin impacts to maintain market access. Across the value chain, the net effect has been heightened attention to contractual flexibility, inventory resilience, and multi-sourcing strategies to ensure uninterrupted procedural capability and stable pricing for clinicians and patients.
Insightful segmentation analysis linking device technologies, procedural approaches, and care settings to clinical use cases and procurement priorities
Technology segmentation reveals differentiated clinical and operational use cases that influence procurement and deployment. Core needle biopsy devices, available in both automated and semi-automated variants, remain the workhorse for percutaneous tissue sampling where larger cores and reproducible sampling trajectories are prioritized; automated units appeal to high-volume settings seeking speed and consistency, while semi-automated systems trade some throughput for lower capital and training burdens. Fine needle aspiration needles, designed as echo enhanced or standard configurations, continue to support cytology-focused workflows and offer advantages in select lesion types where minimal invasiveness and rapid onsite evaluation are critical. Vacuum-assisted systems, offered as handheld or table configured platforms, expand the procedural spectrum by enabling larger-volume sampling and targeted excision that can reduce the need for subsequent diagnostic surgeries.
Procedure type segmentation highlights modality-specific clinical pathways that drive device choice and skill requirements. MRI-guided approaches, whether closed or open bore, are essential for lesions only visible on advanced imaging and demand coordination with radiology scheduling and MRI-safe instrumentation. Palpation-guided techniques persist in low-resource or immediate-access contexts with freehand or grid guided options that balance accessibility and precision. Stereotactic techniques, conducted prone or upright, remain central for calcification sampling and microcalcification-targeted workflows. Ultrasound-guided procedures, utilizing either 2D or 3D guidance, provide the most flexible and widely deployed approach, enabling real-time visualization, needle tracking, and point-of-care diagnostics.
End user segmentation underscores differing procurement priorities across settings. Ambulatory surgery centers, which include diagnostic and outpatient surgery centers, prioritize turnover efficiency, disposable management, and predictable procedure times. Hospitals, both private and public, require devices that integrate into multi-disciplinary pathways, align with institutional quality metrics, and support complex case mixes. Specialty clinics, encompassing oncology and radiology clinics, emphasize diagnostic accuracy, access to advanced modalities, and close collaboration with pathology services to shorten diagnostic intervals and streamline care pathways.
Regional dynamics and distinct adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape procurement, regulation, and clinical workflows
Regional dynamics influence clinical adoption, supply chain design, and regulatory strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical pathways increasingly favor outpatient and ambulatory models with strong payer focus on efficiency and patient experience; manufacturers and distributors must therefore emphasize reliability, consumable cost management, and clinician training to win in this environment. Europe, Middle East & Africa presents a heterogeneous landscape where national reimbursement frameworks, centralized procurement in some markets, and variable access to high-end imaging equipment shape adoption patterns; local regulatory nuances and distribution partnerships are critical for sustained market penetration.
Asia-Pacific demonstrates rapid modernization of imaging infrastructure in urban centers, coupled with a growing emphasis on minimally invasive procedures and domestic manufacturing capabilities. In many markets within the region, cost sensitivity is paired with willingness to adopt technologies that demonstrably reduce downstream surgical burden. Across all regions, regional supply chain resilience, regulatory compliance, and clinician education programs are common success factors for vendors seeking durable presence and clinical trust.
Evolving competitive strategies where product performance, integrated services, and interoperability determine long-term vendor advantage in breast biopsy markets
Competitive behavior in the breast biopsy domain is evolving from product-centric differentiation to ecosystem-centric value propositions. Leading manufacturers are increasingly bundling service agreements, training programs, and integrated disposables management into commercial offers to address hospital and outpatient buyer demands for predictable operating costs and reduced administrative overhead. Strategic partnerships between device makers and imaging system providers are advancing interoperability, enabling tighter integration of lesion targeting data and needle guidance for improved diagnostic yield.
Innovation focus has shifted toward features that reduce procedural variability, such as improved needle visualization, ergonomics that lower clinician fatigue, and device designs that simplify sterilization and inventory handling. Smaller and specialized vendors are finding opportunities by targeting niche clinical indications or by delivering point-of-care solutions that address gaps in access. Meanwhile, procurement sophistication among end users is increasing, with clinical and supply chain leaders jointly evaluating vendor value based on clinical evidence, training support, and lifecycle cost management rather than capital price alone.
Practical recommendations for manufacturers, providers, and purchasers to align innovation, evidence, and supply resilience with evolving clinical and commercial needs
Industry leaders should prioritize a set of pragmatic actions that align commercial, clinical, and operational objectives. First, invest in evidence-generation programs that demonstrate how device features translate to measurable clinical outcomes and operational efficiencies; robust real-world evidence and peer-reviewed clinical collaborations will accelerate clinician adoption. Second, redesign commercial models to emphasize total cost of ownership, offering flexible consumable bundles and service-level agreements that match the financial cadence of ambulatory centers and hospitals alike. Third, strengthen supply chain resilience through multi-sourcing, regional supplier qualification, and inventory optimization to reduce exposure to trade disruptions and tariff volatility.
Manufacturers should also pursue tighter interoperability with imaging platforms and pathology workflows to shorten diagnostic cycles and support integrated care pathways. Training and credentialing programs tailored to different procedure types and care settings will lower adoption barriers and reduce procedural variability. Finally, consider modular product architectures that allow incremental feature rollouts and enable customization for distinct clinical segments, thereby lowering entry barriers for resource-constrained environments while preserving pathways to upgrade as demand for advanced capabilities grows.
Transparent mixed-methods research design combining clinician interviews, procedural observation, and secondary clinical and regulatory sources to validate insights
This research synthesized primary and secondary methods to ensure a balanced understanding of clinical practice, procurement behavior, and technology trends. Primary inputs included structured interviews with radiologists, oncologists, pathology lab directors, ambulatory surgery center administrators, and supply chain leaders to capture operational realities and adoption barriers. These interviews were complemented by observational reviews of procedural workflows and device use in representative clinical settings to contextualize qualitative insights.
Secondary research encompassed peer-reviewed clinical literature, device regulatory filings, clinical guidelines, and publicly available hospital procurement documentation to triangulate trends and validate practice patterns. Findings were subjected to cross-validation through expert advisory panels and scenario testing to assess the robustness of insights across different procedural mixes and regional contexts. Data integrity checks and bias mitigation steps were applied throughout, including respondent sourcing diversity, anonymized synthesis of interview content, and transparent documentation of methodological limitations to support confident decision-making by readers.
A decisive synthesis showing how clinical innovation, operational efficiency, and supply resilience together determine future success in the breast biopsy arena
The breast biopsy landscape is at an inflection where technology, clinical workflow optimization, and commercial strategy intersect to influence future adoption and value creation. Advances in imaging and device design are expanding the range of minimally invasive diagnostic options while shifting procedural volume toward outpatient settings that demand efficiency and predictable costs. Concurrently, supply chain and tariff dynamics have elevated the importance of procurement resilience and total cost evaluation, prompting manufacturers to rethink design, sourcing, and commercial models.
For clinical leaders, the emphasis should remain on diagnostic accuracy, patient experience, and integration of pathology workflows to accelerate time-to-treatment. For commercial leaders, aligning evidence generation with buyer procurement criteria and offering flexible service models will be pivotal. Taken together, these forces create an opportunity for stakeholders who can deliver demonstrable clinical benefit, operational predictability, and adaptable commercial terms to secure sustained adoption and strategic advantage.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
- 2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
- 3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2024
- 3.5. FPNV Positioning Matrix, 2024
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
- 4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Porter’s Five Forces Analysis
- 4.4. PESTLE Analysis
- 4.5. Market Outlook
- 4.5.1. Near-Term Market Outlook (0–2 Years)
- 4.5.2. Medium-Term Market Outlook (3–5 Years)
- 4.5.3. Long-Term Market Outlook (5–10 Years)
- 4.6. Go-to-Market Strategy
- 5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Breast Biopsy Market, by Product Type
- 8.1. Biopsy Needles
- 8.2. Guidance Systems
- 8.3. Biopsy Guns
- 8.4. Consumables & Accessories
- 9. Breast Biopsy Market, by Procedure Type
- 9.1. Core Needle Biopsy
- 9.2. Vacuum-Assisted Biopsy
- 9.3. Fine Needle Aspiration Biopsy
- 9.4. Surgical/Open Biopsy
- 9.4.1. Excisional Biopsy
- 9.4.2. Incisional Biopsy
- 10. Breast Biopsy Market, by Guidance Modality
- 10.1. Ultrasound-Guided Biopsy
- 10.2. Stereotactic X-Ray-Guided Biopsy
- 10.3. MRI-Guided Biopsy
- 11. Breast Biopsy Market, by Biopsy Site
- 11.1. Breast Parenchyma
- 11.2. Axillary & Regional Lymph Nodes
- 11.3. Nipple & Ductal Structures
- 12. Breast Biopsy Market, by End User
- 12.1. Ambulatory Surgery Centers
- 12.2. Hospitals
- 12.3. Specialty Clinics
- 13. Breast Biopsy Market, by Clinical Indication
- 13.1. Early Cancer Screening
- 13.2. Therapy Selection
- 13.3. Recurrence & Treatment Monitoring
- 14. Breast Biopsy Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Breast Biopsy Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Breast Biopsy Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. United States Breast Biopsy Market
- 18. China Breast Biopsy Market
- 19. Competitive Landscape
- 19.1. Market Concentration Analysis, 2024
- 19.1.1. Concentration Ratio (CR)
- 19.1.2. Herfindahl Hirschman Index (HHI)
- 19.2. Recent Developments & Impact Analysis, 2024
- 19.3. Product Portfolio Analysis, 2024
- 19.4. Benchmarking Analysis, 2024
- 19.5. Argon Medical Devices, Inc.
- 19.6. Becton Dickinson and Company
- 19.7. Cook Group Incorporated
- 19.8. Danaher Corporation
- 19.9. Exact Sciences Corporation
- 19.10. FUJIFILM Corporation
- 19.11. GE HealthCare
- 19.12. Hologic, Inc.
- 19.13. Medtronic PLC
- 19.14. Merit Medical Systems, Inc.
- 19.15. Siemens Healthineers AG
- 19.16. Sysmex Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
